Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1990 February; 61(2): 292–297.
PMCID: PMC1971409

Breast cancer screening: its impact on clinical medicine.


Breast cancer screening is generally accepted as an effective means of reducing breast cancer mortality in post-menopausal women. In this analysis the impact of nationwide screening on clinical medicine and the effects for the women involved are quantified. Effect estimates are based on results from screening trials in Utrecht (DOM-project) and Nijmegen, and on bi-annual screening of women aged 50-70. The consequences for health care are based on generally accepted assessment and treatment policies. The number of assessment procedures for non-palpable lesions will increase by 12% per year in the build-up period, and will remain slightly higher. The total number of biopsies in a real population is expected to decrease. Screening will lead to a shift in primary treatment modalities, as 15% of mastectomies will be replaced by breast conserving therapy. The temporary increase in the demand for primary treatment in the first years will be followed by a decrease in the demand for treating women with advanced disease. Favourable effects outweigh the inevitable unfavourable effects, with high quality screening and an appropriate invitation system. Breast cancer screening can also be recommended after considering other consequences than mortality reduction.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, Ljungberg O, Ranstam J, Sigfússon B. Mammographic screening and mortality from breast cancer: the Malmö mammographic screening trial. BMJ. 1988 Oct 15;297(6654):943–948. [PMC free article] [PubMed]
  • Collette HJ, Day NE, Rombach JJ, de Waard F. Evaluation of screening for breast cancer in a non-randomised study (the DOM project) by means of a case-control study. Lancet. 1984 Jun 2;1(8388):1224–1226. [PubMed]
  • Day NE, Williams DR, Khaw KT. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer. 1989 Jun;59(6):954–958. [PMC free article] [PubMed]
  • Gravelle HS, Simpson PR, Chamberlain J. Breast cancer screening and health service costs. J Health Econ. 1982 Aug;1(2):185–207. [PubMed]
  • Habbema JD, van Oortmarssen GJ, van Putten DJ, Lubbe JT, van der Maas PJ. Age-specific reduction in breast cancer mortality by screening: an analysis of the results of the Health Insurance Plan of Greater New York study. J Natl Cancer Inst. 1986 Aug;77(2):317–320. [PubMed]
  • Harris JR, Hellman S, Kinne DW. Limited surgery and radiotherapy for early breast cancer. N Engl J Med. 1985 Nov 21;313(21):1365–1368. [PubMed]
  • Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985 Sep 1;56(5):979–990. [PubMed]
  • Holmberg L, Adami HO, Persson I, Lundström T, Tabar L. Demands on surgical inpatient services after mass mammographic screening. Br Med J (Clin Res Ed) 1986 Sep 27;293(6550):779–782. [PMC free article] [PubMed]
  • Knox EG. Evaluation of a proposed breast cancer screening regimen. BMJ. 1988 Sep 10;297(6649):650–654. [PMC free article] [PubMed]
  • Rosen PP. The pathological classification of human mammary carcinoma: past, present and future. Ann Clin Lab Sci. 1979 Mar-Apr;9(2):144–156. [PubMed]
  • Rosner D, Bedwani RN, Vana J, Baker HW, Murphy GP. Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons. Ann Surg. 1980 Aug;192(2):139–147. [PubMed]
  • Schnitt SJ, Silen W, Sadowsky NL, Connolly JL, Harris JR. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med. 1988 Apr 7;318(14):898–903. [PubMed]
  • Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst. 1982 Aug;69(2):349–355. [PubMed]
  • Skrabanek P. The debate over mass mammography in Britain. The case against. BMJ. 1988 Oct 15;297(6654):971–972. [PMC free article] [PubMed]
  • Tabar L, Duffy SW, Krusemo UB. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol. 1987 Jul;23(7):959–962. [PubMed]
  • Tabár L, Fagerberg CJ, Gad A, Baldetorp L, Holmberg LH, Gröntoft O, Ljungquist U, Lundström B, Månson JC, Eklund G, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985 Apr 13;1(8433):829–832. [PubMed]
  • van der Maas PJ, de Koning HJ, van Ineveld BM, van Oortmarssen GJ, Habbema JD, Lubbe KT, Geerts AT, Collette HJ, Verbeek AL, Hendriks JH, et al. The cost-effectiveness of breast cancer screening. Int J Cancer. 1989 Jun 15;43(6):1055–1060. [PubMed]
  • Verbeek AL, Hendriks JH, Holland R, Mravunac M, Sturmans F, Day NE. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet. 1984 Jun 2;1(8388):1222–1224. [PubMed]
  • Warren R. The debate over mass mammography in Britain. The case for. BMJ. 1988 Oct 15;297(6654):969–970. [PMC free article] [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK